Lantheus Holdings, Inc.

Lantheus Holdings, Inc.

LNTHNYSE / NASDAQHealthcareSmall cap

$102.10$0.00 (0.0%)

Last close · Data as of Nov 20, 2026

Market cap
$6.7B
P/E
28.7x
EV / EBITDA
17.2x
Revenue
$1.5B
Net margin
15.2%
ROCE
20.1%

+90.5% over the last year

Lantheus Holdings, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
+1.7%
3M
+1.9%
6M
+6.3%
1Y
+90.5%
5Y
+255.9%

52-week range

Day change $0.00 (0.0%) from $102 to $102 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in LNTH, bought on each weekday since 2021.

News & filings

What Lantheus Holdings filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

StrengthNet profit more than doubled a year on average over three years.

Concerns (1)

  • Net profit fell 25.2% in fiscal 2025.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide.

Read moreShow less

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. It also provides Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; PYLARIFY AI, an medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer; and flurpiridaz used to assess blood flow to the heart. In addition, it develops PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy to patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent for Tau tangles in Alzheimer's disease; LNTH-2401, a novel radiodiagnostic targeting the gastrin-releasing peptide receptor; LNTH-2402; LNTH-2403; LNTH-2404; LNTH-250; LNTH-2515; and LNTH-1363S, an fibroblast activation protein, alpha, copper-64 labeled PET imaging agent. It has collaboration agreements with GE Healthcare; Curium Pharma; POINT; Regeneron; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

Sector
Healthcare
Shares outstanding
64.6M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$6.7B
P/E
28.7x
P/B
6.1x
EV / EBITDA
17.2x
EV / Sales
4.5x
P/S
4.3x
52-week high
$110.94
52-week low
$53.59

Profitability

Operating margin
20.5%
Net margin
15.2%
EBITDA margin
26.2%
ROE
21.4%
ROCE
20.1%
ROIC
18.4%
ROA
10.5%
Asset turnover
0.69

Growth

Revenue
$1.5B
Revenue growth, 1Y
0.5%
Revenue CAGR, 3Y
18.1%
Net profit growth, 1Y
-25.2%
Free cash flow
$348.6M

Solvency

Current ratio
2.70
Debt / Equity
0.57
Debt / Assets
0.28
CFO / Net profit
1.67
Cash / Market cap
5.4%

Where the revenue went

Of every $100 of FY2025 revenue, $15 was left as net income.

Lantheus Holdings, Inc. income statement flow, FY2025
Lantheus Holdings, Inc. income statement flow, FY2025: flows
FromToAmount
RevenueCost of revenue$599.7M
RevenueGross profit$941.9M
Gross profitOperating expenses$626.4M
Gross profitOperating income$315.6M
Operating incomePretax income$313.8M
Operating incomeInterest and other expense$1.8M
Pretax incomeTax and other$80.2M
Pretax incomeNet income$233.6M

Revenue and net profit

Revenue grew 0.5% in FY2025; net profit is the dashed line.

Lantheus Holdings, Inc. revenue and net profit by fiscal year
Lantheus Holdings, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$935.1M$28.1M
FY2023$1.3B$326.7M
FY2024$1.5B$312.4M
FY2025$1.5B$233.6M

Cash flows

FY2025: $390.1M from operations, $348.6M free after investment (dashed).

Lantheus Holdings, Inc. operating and free cash flow by fiscal year
Lantheus Holdings, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022$281.8M$263.4M
FY2023$305.3M$258.7M
FY2024$544.8M$465.1M
FY2025$390.1M$348.6M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$1.5B+0.5%1Y
EBITDA
$403.6M-21.7%1Y
Net profit
$233.6M-25.2%1Y
Cash from operations
$390.1M-28.4%1Y
Free cash flow
$348.6M-25.0%1Y
Revenue CAGR, 3Y
18.1%
Net profit CAGR, 3Y
102.6%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$1.5B$403.6M$233.6M$348.6M21.4%+0.5%-25.2%

Monthly returns

Month-by-month returns of LNTH across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$2.2B
Liabilities$1.1B
Equity$1.1B
Paid-in capital$888.3M
Retained earnings$679.5M
Treasury stock$477.4M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; LNTH highlighted.

P/E against peers

LNTH trades at 28.7x earnings against a peer median of -13.3x.

  1. Lantheus Holdings, Inc. (this company)28.7x

EV / Sales, for the companies without earnings

Not shown (no positive earnings and no EV / Sales): Vaxcyte, Inc., Apogee Therapeutics, Inc., Spyre Therapeutics, Inc., Immunovant, Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Lantheus Holdings, Inc.LNTHthis company$6.7B28.7x6.1x21.4%17.2x
HealthEquity, Inc.HQY$7.2B33.4x3.4x10.2%16.1x
Oscar Health, Inc.OSCR$7.1B-16.1x7.3x-45.3%—
Vaxcyte, Inc.PCVX$7.0B-9.2x2.6x-28.5%-7.8x
Apogee Therapeutics, Inc.APGE$6.9B-26.8x7.6x-28.3%-23.7x
Spyre Therapeutics, Inc.SYRE$6.8B—9.5x-21.7%—
Arcellx, Inc.ACLX$6.7B-29.4x16.7x-56.9%-30.2x
Immunovant, Inc.IMVT$6.7B-13.3x7.9x-59.3%-10.9x
Hims & Hers Health, Inc.HIMS$6.5B50.5x12.0x23.7%46.1x
Peer median—-13.3x7.7x-28.4%-9.3x

Year-to-date ROI

LNTH since 1 January, against earlier years.

Historical volatility

LNTH's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Lantheus Holdings, Inc. operating margin by fiscal year
Lantheus Holdings, Inc. operating margin by fiscal year
DateOperating margin
FY20223.9%
FY202328.1%
FY202429.2%
FY202520.5%
LineFY2025
Cost of revenueCost Of Revenue$599.7M
Gross profitGross Profit$942.0M
Operating expensesOperating Expense$626.4M
Research and developmentResearch And Development$177.3M
Other operating expensesOther Operating Expenses-$4.7M
Total expensesTotal Expenses$1.2B
Pretax incomePretax Income$313.8M

Learn while you research

Academy chapters picked for Lantheus Holdings, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  3. 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  4. 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  5. 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →